Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection.

A rapid, peripheral disease model utilizing the Bunyavirus, Caraparu, was established in mice for the evaluation of antiviral therapy with immunomodulators. 4-6-week-old B6C3F1 female mice, inoculated intraperitoneally with virus, developed coagulative liver necrosis and died between 4-6 days after infection. This Caraparu disease model was relatively resistant to treatment with immunomodulators, such as ABMP, Ampligen, alpha-interferon (IFN-alpha) or beta-interferon (IFN-beta). However, a significant increase in median survival time (MST) was consistently observed upon treatment with gamma-interferon (IFN-gamma). The nucleoside analog--ribavirin--was highly effective against Caraparu virus in repeated treatment schedules begun on either day -1, day 0, or day +1 of infection. Ribavirin gave little protection when initiation of treatment was delayed until day +2. However, combined treatment with IFN-gamma, starting on day 0 and ribavirin starting on day +2, significantly reduced mortality.
AuthorsM A Brinton, E I Gavin, W K Lo, A J Pinto, P S Morahan
JournalAntiviral research (Antiviral Res) Vol. 20 Issue 2 Pg. 155-71 (Feb 1993) ISSN: 0166-3542 [Print] NETHERLANDS
PMID8460932 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Adjuvants, Immunologic
  • Antiviral Agents
  • Recombinant Proteins
  • Ribavirin
  • Interferon-gamma
  • Adjuvants, Immunologic (pharmacology, therapeutic use)
  • Animals
  • Antiviral Agents (pharmacology, therapeutic use)
  • Bunyaviridae Infections (drug therapy, microbiology)
  • Female
  • Interferon-gamma (pharmacology)
  • Liver (pathology)
  • Liver Diseases (drug therapy, microbiology, pathology)
  • Mice
  • Mice, Inbred Strains
  • Microscopy, Electron
  • Orthobunyavirus (drug effects)
  • Recombinant Proteins
  • Ribavirin (pharmacology)
  • Virus Replication (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: